Stock Comparison

ASTH vs LLY

Astrana Health Inc vs Eli Lilly and Co

The Verdict

ASTH takes this one.

Winner

ASTH

Astrana Health Inc

7.4

out of 10

Solid Pick

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$1.7B

Market Cap

$965.0B

77.7

P/E Ratio

52.6

0.7%

Profit Margin

N/A

2.9%

Return on Equity

N/A

1.3

Debt-to-Equity

N/A

Moderate

Overall Risk

Moderate

7.4

DVR Score

0.5

The Deep Dive

ASTH7.4/10

Astrana Health maintains its high-risk, high-reward profile, leveraging a rapidly expanding value-based care market with a clear strategic vision, particularly in Medicare Advantage and Medicaid. The company exhibits robust revenue growth (56% YoY in FY2025, 52.6% expected Q1 2026) and outperformance against its sector. Analyst consensus remains a 'Strong Buy' with significant upside. However, a m...

Full ASTH Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.